Barclays Maintains Overweight on Legend Biotech, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $65 to $90.
May 19, 2023 | 9:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Legend Biotech and raises the price target from $65 to $90.
The news of Barclays maintaining an Overweight rating and raising the price target for LEGN from $65 to $90 indicates a positive outlook for the stock. This could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100